Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Strategies & Market Trends : InvestRight - Short Term Trading St -- Ignore unavailable to you. Want to Upgrade?

To: KLAW97 who wrote (66)	9/8/1998 9:16:00 AM
From: Jeffrey L. Henken	Respond to of 939

American BioMed, Inc., Receives Patent for Stent Delivery System THE WOODLANDS, Texas, Sept. 8 /PRNewswire/ -- American BioMed, Inc. (OTC Bulletin Board: ABMI - news), today announced it has received a patent from the U.S. Patent and Trademark Office for the company's stent delivery system. This patent, when coupled with the company's two other stent patents, adds greatly to the company's proprietary stent technologies. The patent allows the deployment of the company's dual-coil, self-expanding stent in single or bifurcated models without the use of a balloon. Steven B. Rash, President and CEO of American BioMed stated, ''Our stent delivery system has the capability of deploying single coil or bifurcated coil stents, which is currently not available in the market and gives us a significant competitive advantage.'' ''We intend to develop our proprietary stent technology in order to participate in the rapidly expanding stent market, presently estimated at an annual worldwide market in excess of $2 billion. Furthermore, the company is seeking strategic partners to participate in the development of our stent technology,'' Rash added. Commenting on the market potential, Marshall Kerr, American BioMed's VP of Sales and Marketing stated, ''We believe that the awarding of this latest patent together with previously awarded patents, brings us one step closer to participating in the fast growing stent market.'' Kerr added, ''According to the latest reports, the U.S. stent market alone is forecasted to be $1.3 billion annually.'' Some of the other companies currently involved in the stent market include, Johnson and Johnson (NYSE: JNJ - news), Arterial Vascular Engineering, Inc. (Nasdaq: AVEI - news), Boston Scientific (NYSE: BSX - news), and Guidant Corporation (NYSE: GDT - news). American BioMed, Inc. utilizes state-of-the-art technology to develop, manufacture and market minimally invasive medical devices for the treatment of cardiovascular disease. The Company's products include 100%-silicone catheters, through its Cathlab subsidiary; the Evert-O-Cath(TM), a toposcopic catheter for site-specific drug delivery and fluid removal, the OmniCath(R), an atherectomy catheter designed to remove atherosclerotic plaque from obstructed blood vessels throughout the body; and the OrnniFilter, which is used to prevent blood clots from reaching various organs of the body. The Company has over twenty-five patents and 11 FDA approvals covering its product portfolio, and addresses an annual worldwide market estimated to be in excess of $10 billion. ''Safe Harbor'' statement under the Private Securities Litigation Reform Act of 1995: The statements that are not historical facts contained in the release are forward-looking statements that involve risks and uncertainties including, but not limited to, the results of research and development efforts, the results of preclinical and clinical testing, the effect of regulation by the FDA and other agencies, the impact of competitive product development, commercialization and technological difficulties, the results of financing efforts, the effect of the Company's accounting policies, and other risks detailed in the Company's securities and Exchange Commission filings. biz.yahoo.com ABMI doubled in price one day back in March on what turned out to be an unfounded take over rumor and naked short covering. Just a little insight into the possibilities even with a large float: dailystocks.net Regards, Jeff